Friday - April 17, 2026

Category Archives: Pharmaceuticals & Biotech

Neurostimulation Devices Market Projected to Reach USD 22.3 Billion by 2034: DelveInsight | Medtronic, Boston Scientific, and Abbott

Neurostimulation Devices Market Insights The leading companies in the neurostimulation devices landscape include Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, and LivaNova, which collectively held a market share of approximately 65-70% in 2024. These companies focus on innovation pipelines that … Continue reading →

Active Implantable Medical Devices Market Projected to Reach USD 44.9 Billion by 2032 with a 6.71% CAGR: DelveInsight | Medtronic, Abbott, and Cochlear Ltd.

Active Implantable Medical Devices Market Insights Leading companies operating in the active implantable medical devices market include Medtronic, Abbott, and Cochlear Ltd., all of which are actively pursuing technical innovations and strategic acquisitions to expand their market footprint. The global … Continue reading →

Osteoporosis Pipeline Expands as 30+ Companies Advance Innovative Bone Health Therapies, Finds DelveInsight | Alvotech, Transcenta Holding, GlycoNex

Osteoporosis – Pipeline Insight, 2026 There are 30+ key companies, including Alvotech, Transcenta Holding, GlycoNex, and others, developing therapies for Osteoporosis across multiple stages of clinical development. The competitive landscape is characterized by a focus on novel monoclonal antibodies, biosimilars, … Continue reading →

Traumatic Brain Injury Pipeline Grows as 20+ Pharma Companies Advance Novel TBI Therapies, Finds DelveInsight | Oragenics, SHINKEI Therapeutics, AlzeCure, Algernon Pharmaceutical

Traumatic Brain Injury (TBI) – Pipeline Insight, 2026 There are 20+ key companies, including Oragenics, SHINKEI Therapeutics, AlzeCure, Algernon Pharmaceutical, and others, developing therapies for Traumatic Brain Injury. The current treatment landscape relies on managing symptoms with off-label medications, meaning … Continue reading →

Glucagon-Like Peptide Agonist Clinical Trial Pipeline Accelerates as 45+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s “Glucagon-Like Peptide Agonist Pipeline Insight 2026” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in the Glucagon-Like Peptide Agonist pipeline landscape. It covers the Glucagon-Like Peptide Agonist Pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Autism Spectrum Disorder Clinical Trial Pipeline Gains Momentum: 18+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “Autism Spectrum Disorder Pipeline Insight 2026” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Autism Spectrum Disorder pipeline landscape. It covers the Autism Spectrum Disorder Pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Ulcerative Colitis Clinical Trial Pipeline Expands as 70+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Ulcerative Colitis Pipeline Insight 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in the Ulcerative Colitis Pipeline Landscape. It covers the Ulcerative Colitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Fabry Disease Market Estimated at USD 1.7 Billion in 2024, Reports DelveInsight

Fabry Disease Market Leading organizations engaged in the Fabry disease domain include Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, GREENOVATION BIOTECH GMBH, Shire, Takeda, Amicus Therapeutics, Protalix, uniQure, Codexis, MP6 Therapeutics, CellGenTech, and several … Continue reading →

Hunter Syndrome Market to Surpass USD 1.2 Billion by 2036 | 15+ Emerging Therapies and 10+ Companies Driving Innovation, analyses DelveInsight

Hunter Syndrome Market The major companies operating in the Hunter Syndrome space include Homology Medicine, Denali Therapeutics, Regenxbio, Takeda, JCR Pharmaceuticals, GC Pharma, Sangamo Therapeutics, ArmaGen, and others. In 2023, the United States represented the largest share of the Hunter … Continue reading →